GLP-1 Market
LLY $1417.99 ▲ +0.6% NVO $42.18 ▲ +5.0% PFE $30.79 ▲ +2.6% VKTX $27.97 ▲ +7.2% KLRA $12.80 ▲ +1.7% GPCR $20.36 ▲ +0.0% RHHBY $60.95 ▲ +3.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NTLA-2001

NTLA-2001

Company
Intellia Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 5, 2026

Find a Clinical Trial Near Me

See recruiting studies for NTLA-2001 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06128629

    MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

    Not yet reported Intellia Therapeutics 1200 participants Est. completion 2028-04 138 sites Stand-alone
    Other conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
    View official trial listing →
  • Recruiting NCT NCT06672237

    A Phase 3 Study of NTLA-2001 in ATTRv-PN

    Not yet reported Intellia Therapeutics 60 participants Est. completion 2028-08 14 sites
    Other conditions: Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary, Neurodegenerative Diseases, Neuromuscular Diseases, Nerve Disorders, Nervous System Disease, Nervous System Diseases, Genetic Disease, Inborn, Amyloidosis, Familial, Amyloidosis, Hereditary, Amyloidosis, Polyneuropathies, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Peripheral Nervous System Disease, Peripheral Nervous System Diseases, Metabolism, Inborn Errors, Metabolic Diseases
    View official trial listing →
  • Completed NCT NCT04601051

    Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

    Not yet reported Intellia Therapeutics 72 participants Est. completion 2025-09-12 4 sites Stand-alone
    Other conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
    View official trial listing →
  • Enrolling by invitation NCT NCT05697861

    Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

    Intellia Therapeutics 72 participants Est. completion 2038-03 4 sites
    Other conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.